Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Venetoclax reduces the viability of cancer cells by highly selectively inhibiting the function of the Bcl-2 protein. Venetoclax has a low effect on platelets and has been approved ···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：275
Venetoclax is a novel BCL-2 inhibitor that induces apoptosis in cancer cells by binding to the BCL-2 protein. Venetoclax is widely used in the treatment of hematological malignanci···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：313
Venetoclax is the world's only approved selective inhibitor of Bcl-2 that can induce spontaneous apoptosis of cancer cells by specifically binding to Bcl-2 protein and reduce t···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：326
Venetoclax restores normal apoptosis of cancer cells by blocking the anti-apoptotic function of the BCL-2 protein. Indications include chronic lymphocytic leukemia, acute myeloid l···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：356
Venetoclax is the only approved inhibitor of Bcl-2, which achieves high selectivity for Bcl-2 and reduces platelet damage by introducing indole and azaindole groups, making it suit···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：315
Venetoclax is an oral, small-molecule targeted drug that restores the apoptosis ability of cancer cells by blocking the Bcl-2 protein. It is approved for the treatment of CLL, SLL ···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：350
Venetoclax is the world's first approved selective inhibitor of Bcl-2 that induces apoptosis in cancer cells by highly inhibiting Bcl-2 protein. It has a weak affinity for Bcl-···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：354
Pemigatinib is a targeted therapy drug that is of great significance in the treatment of cholangiocarcinoma.Does Pemigatinib have side effects?Any medication can have some side eff···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：312
Pemigatinibis primarily used for the treatment of adult patients with advanced, metastatic or unresectable cholangiocarcinoma who have received at least one prior systemic therapy ···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：310
Pemigatinibhas demonstrated significant efficacy in the treatment of cholangiocarcinoma with FGFR2 fusion or rearrangement features, among other diseases.What are the side effects ···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：336
Pemigatinib is used in adults to treat bile duct cancer that has spread to other parts of the body (metastatic) or cannot be removed with surgery.Is Pemigatinib good for cholangioc···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：308
Pemigatinib is an effective treatment for advanced or metastatic cholangiocarcinoma caused by FGFR2 fusion or rearrangement.Is the treatment effect of Pemigatinib goodIn the FIGHT-···【more】
Article source：Captain MedicineRelease date：2024-08-14Recommended：301
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：4432025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：6292024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended：852026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：4132025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：4282025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：4152025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4732025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3832025-01-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
